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neoplasms
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The object of this study was the investigation of the risk of occurrence of malignant neoplasms in 508 patients with
Dupuytren’s disease (DD) and in 2157 of their 1st degree relatives. In the first stage of the study, we evaluated the
tumour spectrum as well as the age of the patient at diagnosis of cancers in DD families along with the observed
and expected frequencies of malignancies. In the second stage of the study, we examined the distribution of 20
common mutations/polymorphisms in 12 known cancer susceptibility genes among DD patients and 508 matched
healthy controls. No such study has been published to date. Results. No significant differences were noted between
malignancies diagnosed among members of DD families and the general population. Molecular examination of 20
mutations/polymorphisms in 12 cancer susceptibility genes in Dupuytren’s patients and controls showed a
statistically significant association of one mutation with Dupuytren disease: D312M in XPD (OR = 1.75, p = 0.004). We
observed a tendency toward changed frequencies of occurrence of central nervous system tumors, laryngeal cancer
and non-melanoma skin cancers in DD families. The results of our study indicate a lack of a strong association between
Dupuytren disease and familial cancer risk.
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Dupuytren’s disease (DD) is classified as a benign superfi-
cial fibromatosis, in which excessive proliferation of myo-
fibroblasts result in the formation of nodules and chords
occurs, followed by the development of finger contrac-
tures. Prevalence of DD is geographical and racially re-
lated, with the greatest morbidity in Northern Europe and
it more commonly affects Caucasians than other ethnici-
ties [1]. Dysregulation of specific genes may have an effect
on fibroblast growth characteristics in palmar aponeurosis
leading to their progressive differentiation into myofibro-
blasts and an over-production of type III collagen [2].
There are several similarities between DD and malignant
neoplasms, suggesting a possible association between these
pathologies. Similar to cancer cells, DD fibroblasts are
characterised by infiltrative growth, proliferation, lack of
apoptosis and a tendency towards recurrence. Molecular
studies showed that DD fibroblasts and solid tumor cells
present a similar quality and quantity of chromosomal* Correspondence: debniak@_pum.edu.pl
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unless otherwise stated.aberrations (translocations or trisomies) and the capability
to bind monoclonal antibodies derived form human sarco-
mata [3,4]. Immunochemical studies revealed decreased
expression of Rb and p53 tumor suppressor genes within
these fibroblasts, which is a characteristic feature of many
cancers [5,6]. We have previously reported a possible
association between common variants of DHDH and
the familial occurrence of DD [7]. It was reported that
down-regulation of ALDH2 and DHDH might be associ-
ated with a higher risk of gastrointestinal tract cancers
in alcohol consumers [8,9].
Modest literature data on the possible association be-
tween DD and malignant neoplasms prompted us to ex-
plore this potential association. We have investigated the
risk of occurrence of malignancies at a different site of
origin in a series of 505 Dupuytren patients and 2157 their
1st degree relatives. We evaluated the tumour spectrum,
patients’ age of cancer diagnosis in DD families and the
observed (actual) and expected frequencies of malignan-
cies. Mutations or polymorphisms of many cancer suscep-
tibility genes, such as BRCA1, CDKN2A, XPD, VDR, lead
to tumour development. To evaluate the possible link be-
tween Dupuytren’s disease and malignant neoplasms, wetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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polymorphisms in 12 known cancer susceptibility genes
among patients and 505 matched healthy controls. To




Over a period of five years (form 2008 to 2012), 508 pa-
tients with Dupuytren’s disease, 410 men (81%) and 98
women (19%) with a mean age of 57 years (range 38–86)
were recruited. One hundred and twelve patients under-
went surgery for DD before 2008. They were identified
in the institutional Dupuytren’s disease register and were
invited to participate in the study by mail. Three hun-
dred and ninety six patients were recruited during their
stay in the hospital for operation. These patients were
referred to our institution for Dupuytren’s surgery over the
period of the study 2008–2012. The approval of the Bio-
ethical Council of the local Medical University was ob-
tained and informed consent was obtained from all subjects
before enrolment. During an interview the goals of the
study were explained, genetic counselling was given and a
blood sample was taken for DNA analysis. A detailed family
history and the duration of DD were recorded. The total
number of 1st degree relatives (including patients) was
2662 (1224 females and 1438 males).
The control group comprised 508 healthy adults, 410
men and 98 women with a mean age of 57 years (rangeTable 1 Proportion and age at diagnosis of malignancies of d
polish population
Tumor site Males from Dupuytren’s disease families Population (m





Breast 0 ND^ 0,2
Lungs 21,8 65,38 21,1
Colorectal 13,3 70,21 12,4
Stomach 10,3 63,88 4,9
Prostate 13,9 68,91 13,2
Kidney 3,03 65,8 4,1
Larynx 6,67 64,64 2,7
Skin 3,64 67,5 6,8
Leukaemia 3,03 57,38 2,2
CNS 7,88 56,38 2,4
Pancreas 2,42 ND^ 2,3
Uterus - - -
FGT* - - -
#-general Polish population, according to data published by National Cancer Regist
^ND-not done-mean age was calculated for malignancies affecting at least 5 individ
FGT-female genital tract- site of origin could not be determined more precisely.38–86) who were age matched (+/−2 years) with the DD
patients. The healthy adults were assessed as having a nega-
tive family history for cancer after answering a question-
naire about their family medical history, which was part of
a population-based study of the 1.5 million residents of
West Pomerania province to identify familial aggregations
of malignancies. A blood sample was taken for DNA ana-
lysis from all controls.Methods
In the first stage of the study, we compared frequencies
of malignant tumour occurrence and patient age at diag-
nosis in DD families against those of the general Polish
population. We evaluated malignancies affecting pro-
bands and their 1st degree relatives.
For statistical analyses, the Chi-Square test, U-test and
odds ratio were utilised. Additional analyses performed
in DD families included the comparison of observed fre-
quencies (OF) with expected frequencies (EF) and the rela-
tive risk (RR) of occurrence of malignancies at different
sites of origin. OF and EF were calculated by evaluation of
the total number of family members and affected cases in
different age groups (range of 5 years) in DD families in
comparison to age-specific incidence rates in different age
groups (range of 5 years) per 100 000 people. These calcu-
lations were done by site with individuals registered in the
general population of Poland [10]. Bonferroni correction
was used for multiple testing.ifferent site of origin in Dupuytren’s disease families and





Frequency Mean age at
diagnosis (yrs)
Frequency Mean age at
diagnosis (yrs)
(%) (%)
64,1 28,8 56,95 22,4 60,2
65,9 4,32 63,33 8,6 65,1
67,2 7,91 65,64 10,1 68,3
66,4 3,6 65,8 2,7 68,6
70,1 - - - -
63 4,32 63,67 2,8 65,2
62,4 0 ND^ 0,4 62,2
69,3 1,44 ND^ 7,5 70,2
56,9 2,88 ND^ 1,9 62
55,3 7,91 62,45 2,3 59,3
64,7 5,04 70,43 2,3 69,2
- 4,32 54,5 7,3 63,6
- 12,2 57,94 17,8 68,8
ry [10].
uals.
Table 2 Expected and observed frequencies, related risk of occurrence of malignancies of different site of origin in
Dupuytren’s disease families




Breast Females 40 33 1.212, p = 0.5080 0,04
Lungs Males 36 29 1.241, p = 0.4516 0,002
Females 6 13 0.462, p = 0.1670 0,06
Colorectal Males 22 28 0.786, p = 0.4756 0,09
Females 11 15 0.733, p = 0.5542 0,007
Stomach Males 17 7 2.429, p = 0.651 0,08
Females 5 4 1.250, p = 1.0000 0,004
Melanoma Males 2 2 1.000, p = 0.6168 0,002
Females 1 3 0.333, p = 0.6168 0,02
Kidney Males 5 6 0.833, p = 1.0000 0,008
Females 6 4 1.500, p = 0.7513 0,01
Prostate Males 23 18 1.278, p = 0.5292 0,003
Larynx Males 11 4 2.750, p = 0.1204 0,05
Females 0 1 NA 0,05
CNS Males 13 1 12.00, p = 0.0704* 0,81
Females 11 1 11.00, p = 0.2392* 0,65
Leukaemia Males 5 3 1.667, p = 0.7233 0,004
Females 4 3 1.333, p = 1.0000 0,005
Brain Males 2 3 0.667, p = 1.0000 0,009
Females 4 3 1.333, p = 1.0000 0,005
Bones Males 3 0,3 NA 0,06
Females 1 0,3 NA 0,008
Bladder Males 4 10 0.400, p = 0.0953 0,16
Females 2 3 0.667, p = 1.0000 0,004
NHL Males 4 2 2.000, p = 0.6828 0,006
Females 2 2 1.000, p = 0.6168 0,002
Pancreas Males 4 3 1.333, p = 1.0000 0,003
Females 7 3 2.333, p = 0.3418 0,05
Uterus Females 6 11 0.546, p = 0.3303 0,09
Ovary Females 4 8 0.500, p = 0.3853 0,03
Thyroid Males 5 2 2.267, p = 0.2202 0,02
Females 1 4 0.250, p = 0.3701 0,04
Cervix Females 4 4 1.000, p = 0.4793 0,002
Non-melanoma skin cancer Males 6 9 0.667, p = 0.6046 0,03
Females 2 11 0.182, p = 0.6786* 0,33
Esophagus Males 1 2 0.500, p = 0.9994 0,02
Females 1 0,5 NA 0,004
Gallbladder Males 1 0,4 NA 0,004
Females 0 2 NA 0,14
Liver Males 2 2 1.000, p = 0.6168 0,003
Females 2 1 2.000, p = 1.0000 0,007
HL Males 0 1 NA 0,06
Żyluk et al. Hereditary Cancer in Clinical Practice 2014, 12:6 Page 3 of 7
http://www.hccpjournal.com/content/12/1/6
Table 2 Expected and observed frequencies, related risk of occurrence of malignancies of different site of origin in
Dupuytren’s disease families (Continued)
Females 1 1 1.000, p = 0.4793 0,002
Multiple myeloma Males 0 1 NA 0,06
Females 1 1 1.000, p = 0.4793 0,002
Testicle Males 1 2 0.500, p = 1.0000 0,02
*p-after Bonferroni correction.
** - ≥ 0.7 regarded as statistically powerful.
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prevalence of common alterations in DNA reported in
literature with cancer susceptibility alterations among
– DD patients,
– healthy controls, and
– general authors’ native population
(data obtained from already published reports). We
genotyped founder BRCA1 mutations (5382insC, C61G,
4153delA), common variants of XPD (D312M, K751Q,
R156R), XPC (A499V), XPF (c.207 + 11G > A), NOD2 (30
20insC), CDKN2A (A148T), CHEK2 (CHIVS2, I157T),
VDR (M1T), p53 (P72R), ATM (E1978X), MC1R (R160W,
R151C, R163Q), MTHFR (A222V), and rs67 (rs6983267).
All SNPs were analysed by real-time PCR, using a Light-
Cycler480 from Roche. The analyses were performed
using the TaqMan(R) genotyping assay, which consists of
sequence specific primers and oligonucleotide fluorescent
labelled probes, enabling amplification of the examined
fragments and further allele discrimination. Randomly
selected probes were sequenced to confirm the results
of real-time PCR.
Power calculations were done a posteriori based on the
observed vs expected frequencies, the number of individ-
uals analysed and the threshold p-value (after Bonferroni
correction for multiple testing). The significance threshold
for the p-value was 0.05/20 for analysis of the genetic
markers, and in the case of analysis via the cancer site, the
threshold was 0.05/24 for women and 0.05/22 for men
(0.05 divided by the amount of hypotheses tested for the
same group).
The statistical power was calculated using “pwr” package
of R-version 2.15.0). The alpha (α) value for men was
0.0023 (0.05/22) and for women was 0.0021 (0.05/24).
Results
Evaluation of the mean patients’ age at the diagnosis
performed in our families for cancers affecting at least 5
individuals revealed no significant differences between
malignancies diagnosed among members of DD families
and the general population (Table 1).
Evaluation of tumor spectrum revealed moderate differ-
ences between DD families and the general population:– laryngeal cancer constituted larger proportion of
cancers affecting males from DD families (6.7%) when
compared to males from general population (2,7%);
– central nervous system tumors were overrepresented
among malignancies affecting both males from DD
families (7.9% vs 2.4% in general population) and
females (7.9% vs 2.3%);
– non-melanoma skin cancers were under-represented
in DD families (3,6% of DD male neoplasms vs 6,8%
in the general population and 1,4% of DD female
malignancies vs 7,5% in the Polish population).
We observed 288 cancers among 2662 members of 508
DD families. In comparison to the expected frequency (266
tumours), the difference was not significant (p = 0.35),
neither for males (p = 0.13) nor females (p = 0.90).
A statistical comparison of the observed and ex-
pected frequencies of neoplasms revealed no statisti-
cally significant differences between DD families and the
general population. There was a non-significant over-
representation for central nervous system tumors among
males (OR = 12, p = 0.07) and females (OR = 11, p = 0.24)
from DD familes. We found also a slight tendency for
higher than expected occurrence of laryngeal cancer
among males from DD families (OR = 2.750, p = 0.12). A
reverse tendency was observed for non-melanoma skin
cancers among females (OR = 0.182, p = 0.68).
For analysis by cancer site, the statistical power a
posteriori ranged between 0.81 in the most favourable
case (male central nervous system tumors) and 0.02 in
the least favourable case (several types of cancer, e.g.
cervical cancer) (Table 2).
Molecular examination of 20 mutations/polymorphisms
in 12 cancer susceptibility genes in Dupuytren’s patients
and controls showed a statistically significant association
of one mutation with Dupuytren disease: D312M in XPD
(OR = 1.75, p = 0.004). There were no other differences in
the distribution of cancer susceptibility mutations among
DD families and healthy controls (Table 3). The SNP
rs2020955 within XPF was monomorphic: the frequency
of rs2020955_TT among cases was 499 (100%) and among
controls 1340 (96,75%).
For the analysis of genetic markers, the statistical power
a posteriori ranged between 0.12 in the most favourable
Table 3 Prevalence of the examined mutations/polymorphisms among DD cases and healthy controls
Gene/Mutation Cases Controls p OR
BRCA1/5382insC 2/496 = 0,40% 1/496 = 0,19% 0,5346 2,105
BRCA1/4153delA 3/496 = 0,60% 0/496 = 0%
BRCA1/C61G 0/521 = 0% 1/521 = 0,19%
CHK2/I157T 30/505 = 5,94% 26/505 = 5,15% 0,5416 1,183
CHK2/CHIVS2 5/505 0,99% 4/512 = 0,78% 0,7222 1,270
NOD2/3020insC 43/505 8,51% 45/493 = 9,13% 0,7328 0,9266
XPD/936 (D312M) TT 160/504 31,75% TT 196/484 = 40,49% - -
CT 193/504 = 38,29% CT 193/484 = 39,88% 0,6103 0,9357
CC 151/504 = 29,96% CC 95/484 = 19,63% 0,004* 1,752
XPD/2253 (K751Q) AA 152/503 = 30,22% AA 191/524 = 36,45% - -
AC 268/503 = 53,28% AC 245/524 = 46,76% 0,732* 1,299
CC 83/503 = 16,50% CC 88/524 = 16,79% 0,8998 0,9791
MC1R/R151C CC 455/500 = 91,00% CC 453/500 = 90,60% - -
CT 44/500 = 8,80% CT 45/500 = 9,00% 0,9116 0,9756
TT 1/500 = 0,20% TT 2/500 = 0,40% 0,5631 0,4990
MC1R/V60L GG 427/499 = 85,57% GG 454/512 = 88,67% - -
GT 68/499 = 13,63% GT 53/512 = 10,35% 0,1087 1,366
TT 4/499 = 0,80% TT 5/512 = 0,98% 0,7672 0,8194
MC1R/R163Q GG 460/499 = 92,18% GG 463/503 = 92,05% - -
AG 39/499 = 7,82% AG 37/503 = 7,35% 0,7834 1,068
AA 0/499 = 0% AA 3/503 = 0,60% 0,0840 0,1431
VDR/M1T GG 135/504 = 26,79% GG 161/518 = 31,08% - -
AG 277/504 = 54,96% AG 262/518 = 50,58% 0,1607 1,192
AA 92/504 = 18,25% AA 95/518 = 18,34% 0,9717 0,9943
CDKN2A/A148T 25/504 = 4,96% 23/490 = 4,69% 0,8447 1,060
p53/P72R GG 260/496 = 52,42% GG 269/513 = 52,44% - -
CG 188/496 = 37,90% CG 210/513 = 40,93% 0,3245 0,8807
CC 48/496 = 9,68% CC 34/513 = 6,63% 0,0763 1,509
rs6983267 GG 122/500 = 24,40% GG 135/519 = 26,01% - -
GT 262/500 = 52,40% GT 260/519 = 50,10% 0,4621 1,097
TT 116/500 = 23,20% TT 124/519 = 23,89% 0,7946 0,9623
ATM/E1978X 1/505 = 0,20% 0/505 = 0% NA NA
MTHFR/(A222V CC 191/415 = 46,02% CC 229/500 = 45,80% - -
CT 185/415 = 44,58% CT 227/500 = 45,40% 0,8036 0,9673
TT 39/415 = 9,40% TT 44/500 = 8,80% 0,7540 1,075
XPC/A499V GG 299/489 = 61,15% CC 258/489 = 52,7% - -
AG 167/489 = 34,15% CT 194/489 = 39,6% 0,2083 0,8679
AA 23/489 = 4,70% TT 33/489 = 6,70% 0,3245 0,7098
XPD/rs238406(c.396A > C) CC 173/492 = 35,16% CC 141/492 = 28,66% - -
AC 230/492 = 46,75% AC 267/492 = 54,27% 0,098* 0,7407
AA 89/492 = 18,09% AA 84/492 = 17,07% 0,5994 1,076
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Table 3 Prevalence of the examined mutations/polymorphisms among DD cases and healthy controls (Continued)
XPF/rs762521(c.207 + 11G > A) GG 266/478 = 55,65% GG 280/478 = 58,57% - -
AG 182/478 = 38,07% AG 167/478 = 34,94% 0,2083 1,150
AA 30/478 = 6,28% AA 31/478 = 6,49% 0,8696 0,9644
*p-value after Bonferroni correction.
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favourable case (marker CHK2, variant IVS2 + 1G >A).
Comparatively, for the most favourable case, the mini-
mum sample size for a statistical power a priori of at least
0.7 should have been greater than 1800 cases and an
equivalent number of controls.
Discussion
Assessment of the risk of cancer as a single outcome re-
vealed no statistically significant association between DD
and disease. It indicates that the most common malig-
nancies, such as breast, prostate, lung or colon cancers
are not strongly associated Dupuytren disease. However,
it does not exclude a moderate association for rarer ma-
lignancies. Evaluation of the tumor spectrum of cancers
and comparison of the observed and expected frequen-
cies revealed a tendency towards over-representation of
central nervous system tumors and laryngeal cancer
among male patients in DD families. We also found a
tendency towards under-representation of non-melanoma
skin cancers between female relatives of DD cases. Due to
the relatively small number of cases, both type 1 and 2
statistical errors cannot be excluded; the results thus need
to be verified by examination of a larger series of patients.
The current study lacks the statistical power to confirm if
the absence of any observed association is due to a true
lack of association or rather due to insufficient sample
size. The current research should be considered only as an
exploratory study attempting to reveal interesting tenden-
cies worthy of in-depth analysis at a later stage.
There are only few reports in the literature regarding
the association of Dupuytren’s disease with malignant
neoplasms. The only available studies were based on the
statistical analysis of basic population-characteristic vari-
ables, such as morbidity and mortality rates. Gudmundsson
et al. [1], reported increased total mortality and cancer mor-
tality in men with advanced Dupuytren’s disease in an
Iceland population (hazard ratio 2.0; 95% CI 1.0-3.7). The
incidence of cancer was moderately, but not statistically sig-
nificantly higher than expected from the reference cohort.
There was also an insignificant predominance of digestive
tract cancers among DD patients [1].
Wilbrand et al. [11] determined the risk of cancer in
15 212 patients operated on for DD, by means of record
linkage to the Swedish Cancer Register. The overall rela-
tive risk of cancer in the DD patient population was in-
creased by 24%, compared to the general population.There were significantly increased risks of malignancies
related to smoking, such as buccal, oesophageal, laryn-
geal, gastric, lung and pancreatic cancers. Significantly
increased risks were present for both prostate and rectal
cancer in men, and an increased risk for breast cancer in
women was noted one year or more after surgery for
DD. Based on their findings, the authors suggest that
DD patients display other characteristics, which alter the
risk of malignacies when compared with the general
population [11]. In their later study, these authors re-
ported an increased frequency of soft tissue sarcomas:
fibrosarcoma, malignant fibrous histiocytoma and chon-
drosarcoma among DD patients. These authors noted
that neither smoking, diabetes, nor cancer syndromes
could explain why patients with DD have a higher inci-
dence of sarcoma [3].
Unfortunately, the results of our investigations are not
consistent with those reported above, as we did not find
any significant association between Dupuytren’s disease
and malignant neoplasms.
Examination of mutations/polymorphisms of cancer
susceptibility genes revealed significant association of the
D312M variant of XPD with Dupuytren disease (OR = 1.75;
p = 0,004). The variant is has been reported to predispose
to melanoma, cancers of the lung, breast, liver and stomach
[12-19]. We observed no over-representation of these ma-
lignancies in DD families. This could be explained by low
statistical power of our study and/or the fact that D312M is
associated only with low-to moderate cancer risk.
The results of molecular genotyping of the remaining
mutations/polymorphisms present in cancer susceptibil-
ity genes revealed no differences in the prevalence of the
examined alterations between cases and controls. It seems
that none of the examined alterations in DNA are associ-
ated with Dupuytren disease.
Smoking is well documented risk factor for the devel-
opment of many malignant neoplasms, including lung,
laryngeal, buccal, oesophageal and pancreatic cancers. It
is also known to be a risk factor for Dupuytren’s disease.
In our study we failed to find any significant association
between Dupuytren’s disease and malignant neoplasms,
including those related to smoking habit. We believe that
this potential link need to be further investigated for bet-
ter understanding of the underlying biological mecha-
nisms leading to both diseases.
In conclusion, the results of our study indicate a lack
of a strong association between Dupuytren disease and
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sociation of the D312M variant of the XPD gene with
DD and a tendency toward changed frequencies of oc-
currence of central nervous system tumors, laryngeal
cancer and non-melanoma skin cancers in DD families.
Since Dupuytren contracture is polygenetic, it would be
also interesting to know whether there are interactive ef-
fects between the examined SNPs. As a future option,
large sample sizes are needed to investigate such genetic
interactive effects. Further studies are needed to confirm
the findings and to evaluate whether or not cancer sur-
veillance protocols are justified in these families.
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